Abstract
Gastric adenocarcinoma (GAC) is one of the most aggressive malignancies and has a dismal prognosis. Therefore, multimodality therapies to include surgery, chemotherapy, targeted therapy, immunotherapy, and radiation therapy are needed to provide advantage. For locally advanced GAC (>cT1B), the emerging strategies have included preoperative chemotherapy, postoperative adjuvant chemotherapy, and (occasionally) postoperative chemoradiation in various regions. Several novel therapies have been assessed in clinical trials, but only trastuzumab and ramucirumab (alone and in combination with paclitaxel) have shown overall survival advantage. Pembrolizumab has been approved by the US Food and Drug Administration on the basis of response rate only for patients with microsatellite instability (MSI-H) or if PD-L1 expression is positive (≥1% labeling index in tumor/immune cells in the presence of at least 100 tumor cells in the specimen). Nivolumab has been approved in Japan on the basis of a randomized trial showing significant survival advantage for patients who received nivolumab compared with placebo in the third or later lines of therapy. The cure rate of patients with localized GAC in the West is only about 40% and that for metastatic cancer is very poor (only 2–3%). At this stage, much more target discovery is needed through molecular profiling. Personalized therapy of patients with GAC remains a challenge.
Funder
Myer Fund
Milrod Fund
Caporella family
National Cancer Institute and Department of Defense awards
University of Texas M.D. Anderson Cancer Center (Houston, TX, USA) multidisciplinary grant program
Sultan family
Vanstekelenberg family
Program for Advancing Strategic International Networks to Accelerate the Circulation of Talented Researchers
Oaks family
Schecter Private Foundation
Rivercreek Foundation
Japan Society for the Promotion of Science Overseas Research Fellowships
Cantu family
Dio Fund
Planjery family
Kevin Fund
Smith family
Frazier family
Dallas family
Subject
General Pharmacology, Toxicology and Pharmaceutics,General Immunology and Microbiology,General Biochemistry, Genetics and Molecular Biology,General Medicine
Reference90 articles.
1. Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015: A Systematic Analysis for the Global Burden of Disease Study.;C Fitzmaurice;JAMA Oncol.,2017
2. Epidemiology of gastric cancer.;K Crew;World J Gastroenterol.,2006
3. Rising incidence of adenocarcinoma of the esophagus and gastric cardia.;W Blot;JAMA.,1991
4. Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes.;R Cristescu;Nat Med.,2015
5. Comprehensive molecular characterization of gastric adenocarcinoma.;Nature.,2014
Cited by
23 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献